At a glance
ClinicalIndex Comparison RecordN/ACompleted· 63 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Efficacy of Botulinum Toxin for the Treatment of Dystonia Associated With Parkinson's Disease and Atypical Parkinsonism: a Monocentric Cohort Study With Patient Reported Outcome
In Brief
An observational study for Parkinson Disease and 2 related conditions. Completed, enrolled 63 participants across 1 site.
Detailed Summary
Dystonia is a disabling symptom affecting both patients with idiopathic Parkinson's disease (PD) and atypical parkinsonism (AP). Botulinum toxinum (BoNT), by blocking muscle contraction, is a possible treatment for focal dystonia. The benefit of BoNT treatment has been proven in some focal dystonia associated with PD or AP. The investigators aim to give an overview of the efficacy of BoNT in a variety of focal dystonia in a large cohort of parkinsonian patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsParkinson Disease, Atypical Parkinsonism, Dystonia
CountriesFrance
CollaboratorsAssistance Publique - Hôpitaux de Paris
Timeline
N/ACompletedFinished
201820192020202120222023202420252026
Enrollment StartSep 2017
Primary CompletionFeb 2021
First PostedJul 2021
TodayJul 2026
First PostedJul 2, 2021
Enrollment StartSep 1, 2017
Primary CompletionFeb 11, 2021
TodayJul 2, 2026
Enrollment to primary: 3.4 yearsPosted 5 years ago